LEO Pharma Announces Changes to Executive Leadership
null
Ballerup, 29 January 2025 – Today, LEO Pharma announces the appointment of a new Executive Vice President, North America. Robert Spurr will join the Global Leadership Team and serve as CEO and President, LEO Pharma Inc. United States. Robert succeeds Brian Hilberdink, who will be leaving LEO Pharma to pursue an external opportunity in a large pharmaceutical company.
Robert joined LEO Pharma in 2023 as Vice President of Market Access, Patient Services, Sales, and Health Economics and Outcomes Research (HEOR) and a member of the North America Leadership Team. Prior to LEO Pharma, he previously held numerous senior leadership positions at Novartis, Johnson and Johnson, and Repligen. Robert also served as President of Bausch Healthcare Companies Inc.
“I am thrilled to step into the role of EVP of Region North America and CEO & President of LEO Pharma Inc. US,” said Robert Spurr “As LEO Pharma undergoes significant transformation with a clear strategy for the future, I am eager to leverage my experience to drive our continued success. With a strong growth trajectory and a dedicated team, I am confident we can deliver great results.”
Robert Spurr will officially step into the EVP role on January 29, 2025. Brian Hilberdink’s last day at LEO Pharma will be on February 11, 2025.
“During my tenure at LEO Pharma, I have witnessed the incredible drive and passion across Region North America. I’m proud to have had the opportunity to lead and help propel the Region into a significant growth trajectory,” said Brian Hilberdink, former EVP of Region North America and CEO & President of LEO Pharma Inc. US. “It has not been an easy decision to leave LEO Pharma, and I have every confidence in the future success of the organization.”
“I would like to thank Brian for his key contribution in accelerating LEO Pharma’s growth trajectory in North America and for building a strong team,” said LEO Pharma CEO, Christophe Bourdon. “Robert’s track record and leadership qualities make him ideally suited to his new role. Over the last 18 months I have been truly impressed by his key contributions to the US affiliate. I would like to congratulate him on his appointment and welcome him as a member of LEO Pharma’s Global Leadership Team. His contributions will be instrumental in further strengthening our growth trajectory in North America.”
Kontakter
Jeppe Ilkjær
LEO Pharma, Global Communications
Tel: +45 30 50 20 14
Email: JEILK@leo-pharma.com
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care through innovation for the benefit of people with skin conditions. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. LEO Pharma offers a broad portfolio of treatments, serving 100 million patients annually. Headquartered in Denmark, LEO Pharma has a global team of 4,000 people. In 2023, the company generated net sales of DKK 11.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad
LEO Pharma announces NICE recommendation of reimbursement in England and Wales5.11.2025 12:00:00 CET | Pressemeddelelse
The National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United Kingdom specifically approved for moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 The Technology Appraisal Guidance (TAG) means NHS organisations in England and Wales must now make Anzupgo® ▼(delgocitinib) cream available for healthcare professionals to prescribe. CHE affects around 4.4 million2,3 adults in the UK, with 70% of those with severe forms reporting problems performing everyday activities4, and 58% saying it interferes with their ability to work5.
LEO Pharma strengthens leadership in medical dermatology with the appointment of Sophie Lamle as Chief Development Officer3.11.2025 12:00:00 CET | Pressemeddelelse
Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation. Her appointment will further strengthen LEO Pharma’s Search & Develop innovation model, unlocking value with a focus on differentiated assets.
LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China16.10.2025 15:30:00 CEST | Pressemeddelelse
LEO Pharma is seeking to expand the availability of Anzupgo® (delgocitinib) cream to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA), which has been accepted for review for adult patients with moderate to severe chronic hand eczema. The NDA is supported by results from DELTA China, a phase 3 trial with Anzupgo in Chinese adults with moderate to severe chronic hand eczema (CHE)1 along with the full clinical program of delgocitinib, which includes data from DELTA 1,2 and 3, DELTA Force and DELTA Teen.2-7 The Anzupgo NDA submission demonstrates LEO Pharma's commitment to providing additional treatment options for patients living with skin diseases in China.
LEO Pharma closes deal for Spevigo®1.10.2025 09:00:00 CEST | Pressemeddelelse
Adding Spevigo® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the treatment and prevention of GPP flares Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseases
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum